STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-3/Line 1-3, 29-55	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3/Line 50-55	Paragraph 1-4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	7/Line 82-102	Introduction
Objectives	3	State specific objectives, including any prespecified hypotheses	7/Line 102-105	Introduction
Methods				
Study design	4	Present key elements of study design early in the paper	8/Line 111-122	Patients and Methods
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8/Line 111-122	Patient selection and data collection
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	8/Line 112-118	Patient selection and data collection
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	Not applicable	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8/Line 123-132	Perioperative outcomes
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8/Line 118-132	Patient selection and data collection, perioperative
Bias	9	Describe any efforts to address potential sources of bias	9-10/Line 147-172	Statistical analysis
Study size	10	Explain how the study size was arrived at	9/Line 133-140	Sample size estimation
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-10/Line 142-190	Statistical analysis

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-12/Line 142-190	Statistical analysis
		(b) Describe any methods used to examine subgroups and interactions	10-12/Line 157-190	Statistical analysis
		(c) Explain how missing data were addressed	11/Line 166-172	Statistical analysis
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	9-12/Line 142-190	Statistical analysis
		(e) Describe any sensitivity analyses	10-11/Line 157-161	Statistical analysis
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12/Line 193	Baseline characteristics and perioperative
		(b) Give reasons for non-participation at each stage	12/Line 193	Baseline characteristics
		(c) Consider use of a flow diagram	12/Line 193-194	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12/Line 194-199	Baseline characteristics and perioperative
		(b) Indicate number of participants with missing data for each variable of interest	11/Line 166-172	Statistical analysis
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	Not applicable	Not applicable-
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	12-13/Line 194-206	Baseline characteristics
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	Not applicable	Not applicable
		Cross-sectional study—Report numbers of outcome events or summary measures	Not applicable	Not applicable
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13/Line 207-217	Baseline characteristics and perioperative,
		(b) Report category boundaries when continuous variables were categorized	Not applicable	Not applicable
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13-14/Line 218-232	Mediation effects
Discussion				
Key results	18	Summarise key results with reference to study objectives	14/Line 234-240	Discussion, paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	19/Line 329-338	Paragraph 1 on this page

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-18/Line 241-328	Discussion
Generalisability	21	Discuss the generalisability (external validity) of the study results	14-18/Line 241-328	Discussion
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	20/Line 348-350	Funding

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/tlcr-24-336
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.